Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled·Investor's Business Daily
In this article:

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

Advertisement